Fig. 3: MYCN directly upregulates FA transporter SLC27A2.

a FA transporters (SLC27A1–6, CD36) and ODC1 mRNA expression in SK-N-AS MYCN-ER^™ cells (1 µM 4-OHT for 0, 24, 48 h). Mean±SEM (n = 3); two-way ANOVA with Dunnett’s multiple comparisons test. b FA transporters (SLC27A1–6, CD36) mRNA expression in Tet21/N cells (±2 µg/mL DOX for 24 h). Mean±SEM (n = 3); two-sided unpaired t-test. MYCN protein expression in Tet21/N cells (−DOX, MYCN-ON and +DOX, MYCN-OFF). c MYCN ChIP-qPCR assays in TET21/N cells (±2 µg/mL DOX for 48 h). Input and MYCN ChIP samples were analyzed by qPCR using specific primers for SLC27A1–6 and CD36. Mean±SD (n = 3); two-way ANOVA with Dunnett’s multiple comparisons test. d Gene expression analysis in Cohort 1 (GSE45547). Left, correlation matrix of transporter gene expression, MYCN expression/activity, and c-MYC expression. Correlations with p-values < 0.05 are represented in the heatmap. Red = positive; blue = negative correlation. Middle, SLC27A2 expression in MNA (n = 93) and non-MNA patients (n = 550). Two-sided unpaired Welch’s t-test. Right, SLC27A2 expression in stage 1–4 S patients (stage 1: n = 153; stage 2: n = 113; stage 3: n = 91; stage 4: n = 214; stage 4 s: n = 78). One-way ANOVA with Tukey’s multiple comparisons test. Box plots indicate median (middle line), 25th and 75th percentiles (box), as well as min and max (whisker). e, f Survival analyses in Cohort 1 (GSE45547). e OS and EFS rates for stage 1–4 S and stage 3–4 patients with high (top third) or low (bottom third) SLC27A2 expression. f OS and EFS predictions for genes in the long-chain FA transport geneset (GO: 0015909); –log₁₀(p-value). Kaplan–Meier method was used to plot survival curves, and log-rank test was used for statistical analysis. Red=high expression has poor prognosis (p < 0.05); blue = low expression has poor prognosis (p < 0.05); gray = no significance. FC fold change, OS overall survival, EFS event-free survival. Source data are provided in the Source Data file.